Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma

[...]the evidence about the applicability and predictive performance of the R2-ISS in the real world was limited. [...]this study aimed to determine whether R2-ISS was valid for patients with MM undergoing real-world treatment patterns in China. Compared to these patients in R2-ISS I, there were sig...

Full description

Saved in:
Bibliographic Details
Published inChinese medical journal Vol. 136; no. 14; pp. 1744 - 1746
Main Authors Yan, Wenqiang, Fan, Huishou, Xu, Jingyu, Liu, Jiahui, Li, Lingna, Du, Chenxing, Deng, Shuhui, Sui, Weiwei, Xu, Yan, Zou, Dehui, Qiu, Lugui, An, Gang
Format Journal Article
LanguageEnglish
Published China Lippincott Williams & Wilkins Ovid Technologies 20.07.2023
Lippincott Williams & Wilkins
Wolters Kluwer
Subjects
Blood diseases
Correspondence
Hematology
Medical prognosis
Multiple myeloma
China
Online AccessGet full text

Cover

More Information
Summary:[...]the evidence about the applicability and predictive performance of the R2-ISS in the real world was limited. [...]this study aimed to determine whether R2-ISS was valid for patients with MM undergoing real-world treatment patterns in China. Compared to these patients in R2-ISS I, there were significantly higher risks of death of patients in R2-ISS III (hazard ratio [HR]: 5.07, 95% confidence interval [95% CI]: 2.33–11.03; P <0.001) and of R2-ISS IV group (HR: 9.67, 95% CI: 4.22–22.14; P <0.001). [...]several multicenter studies, including patients among diverse regions, should be conducted to further assess the most appropriate weighted score of 1q21+ in the future. [...]fewer than 50% of patients with MM in our study had received ASCT, thus limiting the extrapolation of our results to
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0366-6999
2542-5641
DOI:10.1097/CM9.0000000000002735